Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;25(5):e3484.
doi: 10.1002/jgm.3484. Epub 2023 Feb 24.

Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment

Nasim Adabi  1 , Safoora Pordel  2   3 , Mohammad Ali Rezaee  2 , Fatemeh Sadat Shobeiri  4 , Saeideh Sadat Shobeiri  2   4
Affiliations
Review

Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment

Nasim Adabi et al. J Gene Med. 2023 May.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy approach that has played a tremendous role in the battle against cancer for years. Since the CAR T lymphocytes are unrestricted-major histocompatibility complex T lymphocytes, they could identify more targets than natural T cells, resulting in practical and widespread functions. The good prospects of CAR T-cell therapy in oncology can be additionally applied to treat other diseases such as autoimmune and infectious diseases. CAR-T cell-derived immunotherapy for autoimmune disorders can be allocated to CAR-Tregs and chimeric autoantibody receptor T cells. Other generations of CARs target human immunodeficiency virus (HIV) proteins. In this review, we summarize CAR-T cell therapies in autoimmune disorders and HIV infection.

Keywords: CAR-T; Tregs; autoimmune diseases; chimeric antigen receptor; cytotoxic T cells; human immunodeficiency virus; immunotherapy.

PubMed Disclaimer

References

REFERENCES

    1. Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250. doi:10.3389/fimmu.2019.02250
    1. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64-73. doi:10.1056/NEJMra1706169
    1. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3-S9. doi:10.1002/ajh.25418
    1. Wei J, Guo Y, Wang Y, et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021;18(4):792-804. doi:10.1038/s41423-020-00555-x
    1. Wang Y, Zhang W-Y, Han Q-W, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2014;155(2):160-175. doi:10.1016/j.clim.2014.10.002

MeSH terms

Substances

LinkOut - more resources